MVX 01
Alternative Names: MVX-01Latest Information Update: 20 Mar 2023
At a glance
- Originator Matrivax
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pneumococcal infections
Most Recent Events
- 16 Mar 2023 Phase-I clinical trials in Pneumococcal infections (Prevention) in USA (Parenteral)
- 30 Sep 2020 Matrivax announces intention to submit IND application to the US FDA for Pneumococcal infections in USA in 2020 (Parenteral)
- 14 Jan 2020 Preclinical trials in Pneumococcal infections in USA (Parenteral) before January 2020 (Matrivax pipeline, January 2020)